Literature DB >> 10390249

Sensitivity of amoxicillin-resistant Helicobacter pylori to other penicillins.

M P Dore1, D Y Graham, A R Sepulveda, G Realdi, M S Osato.   

Abstract

The sensitivities to penicillins and to a penicillin and beta-lactamase inhibitor combination agent were determined for Helicobacter pylori strains that were sensitive, moderately resistant, or highly resistant to amoxicillin. All strains were resistant to nafcillin and oxacillin. Moderately resistant strains showed an intermediate zone of inhibition to ticarcillin, mezlocillin, piperacillin, and amoxicillin-clavulanic acid. High-level resistance was associated with the smallest zone size for all penicillins tested.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10390249      PMCID： PMC89370     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

Review 1.  Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance.

Authors:  D Y Graham; W A de Boer; G N Tytgat
Journal:  Am J Gastroenterol       Date:  1996-06       Impact factor: 10.864

2.  Review of Helicobacter pylori eradication regimens.

Authors:  P Unge
Journal:  Scand J Gastroenterol Suppl       Date:  1996

Review 3.  Resistance of Helicobacter pylori to antibiotics.

Authors:  F Mégraud
Journal:  Aliment Pharmacol Ther       Date:  1997-04       Impact factor: 8.171

4.  Use of penicillin-gradient and replicate plates for the demonstration of tolerance to penicillin in streptococci.

Authors:  K S Kim; B F Anthony
Journal:  J Infect Dis       Date:  1983-09       Impact factor: 5.226

5.  Amoxycillin tolerance in Helicobacter pylori.

Authors:  M P Dore; M S Osato; G Realdi; I Mura; D Y Graham; A R Sepulveda
Journal:  J Antimicrob Chemother       Date:  1999-01       Impact factor: 5.790

6.  Antimicrobial susceptibility testing of Helicobacter pylori. Comparison of E-test, broth microdilution, and disk diffusion for ampicillin, clarithromycin, and metronidazole.

Authors:  C Y Hachem; J E Clarridge; R Reddy; R Flamm; D G Evans; S K Tanaka; D Y Graham
Journal:  Diagn Microbiol Infect Dis       Date:  1996-01       Impact factor: 2.803

Review 7.  Eradication of Helicobacter pylori: an objective assessment of current therapies.

Authors:  J G Penston; K E McColl
Journal:  Br J Clin Pharmacol       Date:  1997-03       Impact factor: 4.335

Review 8.  Treatment of Helicobacter pylori infection: a review of the world literature.

Authors:  R W van der Hulst; J J Keller; E A Rauws; G N Tytgat
Journal:  Helicobacter       Date:  1996-03       Impact factor: 5.753

9.  Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors:  C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191
  9 in total
  5 in total

1.  In vitro activity of a novel antimicrobial agent, TG44, for treatment of Helicobacter pylori infection.

Authors:  Osamu Kamoda; Kinsei Anzai; Jun-ichi Mizoguchi; Masatoshi Shiojiri; Toshiharu Yanagi; Takeshi Nishino; Shigeru Kamiya
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Triple, standard quadruple and ampicillin-sulbactam-based quadruple therapies for H. pylori eradication: a comparative three-armed randomized clinical trial.

Authors:  Seyed Amir Mirbagheri; Mehrdad Hasibi; Mehdi Abouzari; Armin Rashidi
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

3.  Characterization of an In vitro-selected amoxicillin-resistant strain of Helicobacter pylori.

Authors:  C R DeLoney; N L Schiller
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

4.  Furazolidone, co-amoxiclav, colloidal bismuth subcitrate, and esomeprazole for patients who failed to eradicate Helicobacter pylori with triple therapy.

Authors:  Zaigham Abbas; Javed Yakoob; Shahab Abid; Wasim Jafri; Muhammad Islam; Zahid Azam; Imran Hilal
Journal:  Dig Dis Sci       Date:  2008-12-05       Impact factor: 3.199

5.  Levofloxacin-amoxicillin/clavulanate-rabeprazole versus a standard seven-day triple therapy for eradication of Helicobacter pylori infection.

Authors:  Ming-Cheh Chen; Wei-Yi Lei; Jen-Shung Lin; Chih-Hsun Yi; Deng-Chyang Wu; Chi-Tan Hu
Journal:  Biomed Res Int       Date:  2014-06-05       Impact factor: 3.411
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.